Key Takeaways
- • Xcellerant Ventures announced a $1 million Fund I investment in Geneticure, a Scottsdale, Arizona-based precision medicine company.
- • Geneticure's non-invasive cheek swab test analyzes four physiologic pathways to predict whether patients with resistant hypertension will respond to renal denervation (RDN), an FDA-approved procedure.
- • The company estimates that more than 10 million of the approximately 35 million eligible U.S. patients may see no benefit from RDN, a gap its responder score aims to address.
- • The funding will support commercial scaling and a new clinical laboratory in Arizona.
Summary
Xcellerant Ventures has announced a $1 million Fund I investment in Geneticure, a precision medicine company based in Scottsdale, Arizona, that develops tests predicting patient response to hypertension treatments. According to the announcement, the capital will accelerate Geneticure's commercial scaling and support a new clinical laboratory in Arizona, which the company cites as contributing to the state's life sciences ecosystem.
Geneticure's core product is a non-invasive cheek swab test that analyzes four physiologic pathways. The test is designed to predict whether a patient with resistant hypertension will respond to renal denervation (RDN), an FDA-approved procedure. The source notes roughly 35 million eligible U.S. patients for RDN, and states that more than 10 million of them may see no benefit from the procedure.
Geneticure's responder score is positioned as a tool that gives physicians greater confidence in patient selection, which the company argues can lower payer costs and support broader clinical adoption of RDN. The article does not disclose the investment terms beyond the $1 million amount, the size of Fund I, or the company's valuation.
Geneticure's core product is a non-invasive cheek swab test that analyzes four physiologic pathways. The test is designed to predict whether a patient with resistant hypertension will respond to renal denervation (RDN), an FDA-approved procedure. The source notes roughly 35 million eligible U.S. patients for RDN, and states that more than 10 million of them may see no benefit from the procedure.
Geneticure's responder score is positioned as a tool that gives physicians greater confidence in patient selection, which the company argues can lower payer costs and support broader clinical adoption of RDN. The article does not disclose the investment terms beyond the $1 million amount, the size of Fund I, or the company's valuation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.